Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

OfficialStocktwitsUser May. 25 at 2:38 PM

$AYTU RSI: 26.32, MACD: -0.1159 Vol: 0.19, MA20: 2.38, MA50: 2.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Henry20feb_ May. 23 at 8:56 AM

$AYTU AYTU has shown characteristics of a possible double-bottom accumulation base: first washout near long-term lows / rebound attempt / second successful support hold / followed by recovery toward resistance. The structure is not as clean or mature as stronger biotech reversals, but technically: sellers appear less aggressive on retests / downside momentum has slowed / volatility compression has increased. That often precedes larger directional moves. Aytu now needs a convincing neckline breakout with sustained volume! 🚀 (Thanks to ChatGPT)

1 · Reply

focafoca99 May. 18 at 9:03 PM

$AYTU joins the Lytham Partners Spring 2026 Investor Conference on May 28. https://www.rapidticker.com/news/aytu-aytu-biopharma-to-participate-in-7de3f2

0 · Reply

Telorino May. 13 at 10:52 PM

$AYTU going from bad to worse! Further dilution coming… This will R/S very, very soon! Serious ongoing financial concern here… Chapter 11 if the dilution doesn’t work…

0 · Reply

focafoca99 May. 13 at 10:40 PM

$AYTU released its fiscal 2026 third-quarter results and held a conference call on May 13. https://www.rapidticker.com/news/aytu-sec-filing-0ed68c

0 · Reply

EarningsInsider May. 13 at 9:33 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-aytu-bioscience-inc-stock/ $AYTU Aytu BioPharma Earnings Transcript

0 · Reply

focafoca99 May. 13 at 8:19 PM

$AYTU details its fiscal 2026 third-quarter results, reporting $12.4 million net revenue and a $5.6 million loss as it ramps up the EXXUA https://www.rapidticker.com/news/aytu-aytu-biopharma-reports-fiscal-2026-baaadf

0 · Reply

brucino May. 13 at 11:10 AM

$AYTU today earning?

1 · Reply

Alain_Simard May. 12 at 1:37 PM

$AYTU this 💩is at least consistent 💩

0 · Reply

LizardLicker26 May. 12 at 12:35 AM

$AYTU took a crazy 💩 today and I could swear it spelled Disbrow.

0 · Reply

Aytu BioPharma Transcript: Lytham Partners Spring 2026 Investor Conference

May 18, 2026, 4:05 PM EDT - 13 days ago

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

2026-05-13T21:11:01.000Z - 18 days ago

Aytu BioPharma reports Q3 EPS (53c), consensus (43c)

May 13, 2026, 4:30 PM EDT - 18 days ago

Aytu BioPharma Earnings Call Transcript: Q3 2026

May 13, 2026, 4:30 PM EDT - 18 days ago

Aytu BioPharma Earnings release: Q3 2026

May 13, 2026, 4:30 PM EDT - 18 days ago

Aytu BioPharma Quarterly report: Q3 2026

May 13, 2026, 4:05 PM EDT - 18 days ago

Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

May 12, 2026, 7:00 AM EDT - 20 days ago

Aytu BioPharma Slides: Corporate presentation

May 6, 2026, 4:05 PM EDT - 25 days ago

Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

Apr 3, 2026, 7:00 AM EDT - 2 months ago

Aytu BioPharma Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 2 months ago

Aytu BioPharma Slides: Corporate presentation

2026-02-03T21:50:30.000Z - 4 months ago

Aytu BioPharma reports Q2 EPS ($1.05) vs. 13c last year

Feb 3, 2026, 4:30 PM EST - 4 months ago

Aytu BioPharma Earnings Call Transcript: Q2 2026

Feb 3, 2026, 4:30 PM EST - 4 months ago

Aytu BioPharma Quarterly report: Q2 2026

Feb 3, 2026, 4:30 PM EST - 4 months ago

Aytu BioPharma Earnings release: Q2 2026

Feb 3, 2026, 4:05 PM EST - 4 months ago

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Feb 3, 2026, 4:00 PM EST - 4 months ago

Aytu BioPharma Slides: Corporate presentation

Jan 27, 2026, 4:05 PM EST - 4 months ago

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan 20, 2026, 4:05 PM EST - 4 months ago

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Jan 20, 2026, 11:00 AM EST - 4 months ago

Aytu BioPharma Transcript: Investor Day 2026

Jan 20, 2026, 11:00 AM EST - 4 months ago

Aytu BioPharma Slides: FY 2026

2026-01-20T14:20:18.000Z - 4 months ago

Aytu BioPharma announces nationwide commercial launch of EXXUA

Jan 15, 2026, 5:00 PM EST - 4 months ago

Aytu BioPharma Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 13, 2026, 4:15 PM EST - 4 months ago

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 12, 2026, 8:00 AM EST - 5 months ago

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Dec 18, 2025, 9:00 AM EST - 5 months ago

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

2025-12-15T14:20:55.000Z - 6 months ago

Aytu BioPharma announces commercial availability of EXXUA tablets

Dec 15, 2025, 9:00 AM EST - 6 months ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Nov 24, 2025, 4:05 PM EST - 6 months ago

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 18, 2025, 7:00 AM EST - 6 months ago

Aytu BioPharma Slides: Corporate presentation

Nov 13, 2025, 4:30 PM EST - 7 months ago

Aytu BioPharma Earnings Call Transcript: Q1 2026

Nov 13, 2025, 4:30 PM EST - 7 months ago

Aytu BioPharma Quarterly report: Q1 2026

Nov 13, 2025, 4:30 PM EST - 7 months ago

Aytu BioPharma Earnings release: Q1 2026

Nov 13, 2025, 4:05 PM EST - 7 months ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 7 months ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

2025-10-28T13:20:53.000Z - 7 months ago

Aytu BioPharma announces patent term extension for EXXUA

Oct 28, 2025, 9:00 AM EDT - 7 months ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 24, 2025, 8:00 AM EDT - 7 months ago

Aytu BioPharma Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 7 months ago

Aytu BioPharma Proxy statement: Proxy Filing

Oct 22, 2025, 2:30 PM EDT - 7 months ago

Aytu BioPharma Transcript: Planet MicroCap Showcase: TORONTO 2025

Oct 10, 2025, 9:00 AM EDT - 8 months ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

2025-10-01T14:40:36.000Z - 8 months ago

Aytu BioPharma management to meet with Lake Street

Sep 30, 2025, 2:45 PM EDT - 8 months ago

Aytu BioPharma Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 25, 2025, 2:00 PM EDT - 8 months ago

Aytu BioPharma Transcript: MicroCap Rodeo Fall Conference

2025-09-25T12:05:29.000Z - 8 months ago

Aytu BioPharma price target lowered to $7 from $9 at Maxim

Sep 24, 2025, 4:15 PM EDT - 8 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

2025-09-24T16:16:41.000Z - 8 months ago

Aytu BioPharma price target lowered to $7 from $9 at Maxim

Sep 23, 2025, 4:30 PM EDT - 8 months ago

Aytu BioPharma Earnings Call Transcript: Q4 2025

Sep 23, 2025, 4:30 PM EDT - 8 months ago

Aytu BioPharma Annual report: Q4 2025

Sep 23, 2025, 4:30 PM EDT - 8 months ago

Aytu BioPharma Earnings release: Q4 2025

Sep 23, 2025, 4:05 PM EDT - 8 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 9 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

2025-07-08T17:45:24.000Z - 11 months ago

Aytu BioPharma management to meet with Maxim

2025-07-01T12:55:58.000Z - 11 months ago

Aytu BioPharma initiated with a Buy at Lake Street

2025-06-30T09:20:10.000Z - 1 year ago

Aytu BioPharma initiated with a Buy at Ascendiant

2025-06-25T12:30:52.000Z - 1 year ago

Aytu BioPharma appoints Gerwin Westfield as SVP, scientific affairs

Jun 25, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

2025-06-23T17:53:35.000Z - 1 year ago

Aytu BioPharma expands, extends lending agreement with Eclipse

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 11, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Transcript: Investor Update

Jun 9, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

2025-06-06T12:45:21.000Z - 1 year ago

Aytu BioPharma 9.6M share Secondary priced at $1.50

2025-06-06T12:15:35.000Z - 1 year ago

Aytu BioPharma enters exclusive agreement with Fabre-Kramer Pharmaceuticals

2025-06-06T12:15:25.000Z - 1 year ago

Aytu BioPharma prices 9.6M shares at $1.50 in upsized public offering

2025-06-06T12:15:20.000Z - 1 year ago

Aytu BioPharma announces exclusive commercialization agreement for Exxua

Jun 6, 2025, 8:01 AM EDT - 1 year ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Registration statement: Registration Filing

2025-06-02T21:20:08.000Z - 1 year ago

Aytu BioPharma files to sell 6.74M shares of common stock

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Registration statement: Registration Filing

May 14, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q3 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Quarterly report: Q3 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings release: Q3 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Aytu BioPharma Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

2025-04-14T22:15:09.000Z - 1 year ago

Aytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designation

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Aytu BioPharma Proxy statement: Proxy Filing

Feb 12, 2025, 4:03 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 12, 2025, 4:00 PM EST - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q2 2025

Feb 12, 2025, 4:00 PM EST - 1 year ago

Aytu BioPharma Quarterly report: Q2 2025

Feb 12, 2025, 4:00 PM EST - 1 year ago

Aytu BioPharma Earnings release: Q2 2025

Feb 5, 2025, 5:50 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q1 2025

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aytu BioPharma Quarterly report: Q1 2025

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aytu BioPharma Earnings release: Q1 2025

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 16, 2024, 2:00 PM EDT - 1 year ago

Aytu BioPharma Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Registration statement: Registration Filing

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings Call Transcript: Q4 2024

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Aytu BioPharma Earnings release: Q4 2024

Sep 26, 2024, 4:30 PM EDT - 1 year ago

Aytu BioPharma Annual report: Q4 2024

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Registration statement: Registration Filing

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 15, 2024, 12:15 PM EDT - 1 year ago

Aytu BioPharma Transcript: Sidoti Micro-Cap Virtual Conference

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 4:30 PM EDT - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q3 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Aytu BioPharma Quarterly report: Q3 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Aytu BioPharma Earnings release: Q3 2024

May 15, 2024, 4:05 PM EDT - 2 years ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 10, 2024, 8:00 AM EDT - 2 years ago

Aytu BioPharma Proxy statement: Proxy Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Aytu BioPharma Proxy statement: Proxy Filing

May 8, 2024, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 4, 2024, 4:40 PM EDT - 2 years ago

Aytu BioPharma Transcript: Emerging Growth Conference

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q2 2024

Feb 14, 2024, 4:30 PM EST - 2 years ago

Aytu BioPharma Quarterly report: Q2 2024

Feb 14, 2024, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings release: Q2 2024

Feb 14, 2024, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Feb 1, 2024, 11:45 AM EST - 2 years ago

Aytu BioPharma Transcript: Lytham Partners 2024 Select Conference

Jan 23, 2024, 9:00 AM EST - 2 years ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings Call Transcript: Q1 2024

Nov 14, 2023, 4:30 PM EST - 2 years ago

Aytu BioPharma Quarterly report: Q1 2024

Nov 14, 2023, 4:30 PM EST - 2 years ago

Aytu BioPharma Earnings release: Q1 2024

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

OfficialStocktwitsUser May. 25 at 2:38 PM

0 · Reply

Henry20feb_ May. 23 at 8:56 AM

1 · Reply

focafoca99 May. 18 at 9:03 PM

$AYTU joins the Lytham Partners Spring 2026 Investor Conference on May 28. https://www.rapidticker.com/news/aytu-aytu-biopharma-to-participate-in-7de3f2

0 · Reply

Telorino May. 13 at 10:52 PM

$AYTU going from bad to worse! Further dilution coming… This will R/S very, very soon! Serious ongoing financial concern here… Chapter 11 if the dilution doesn’t work…

0 · Reply

focafoca99 May. 13 at 10:40 PM

$AYTU released its fiscal 2026 third-quarter results and held a conference call on May 13. https://www.rapidticker.com/news/aytu-sec-filing-0ed68c

0 · Reply

EarningsInsider May. 13 at 9:33 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-aytu-bioscience-inc-stock/ $AYTU Aytu BioPharma Earnings Transcript

0 · Reply

focafoca99 May. 13 at 8:19 PM

0 · Reply

brucino May. 13 at 11:10 AM

$AYTU today earning?

1 · Reply

Alain_Simard May. 12 at 1:37 PM

$AYTU this 💩is at least consistent 💩

0 · Reply

LizardLicker26 May. 12 at 12:35 AM

$AYTU took a crazy 💩 today and I could swear it spelled Disbrow.

0 · Reply

Rogue23 May. 11 at 11:27 PM

$AYTU

0 · Reply

Merlintrader May. 8 at 7:50 PM

$CING Cingulate ( $CING ) vs Aytu BioPharma ( $AYTU ): What a Commercial ADHD Peer Can — and Cannot — Tell Us Before CING’s May 31 PDUFA https://www.merlintrader.com/cingulate-vs-aytu-biopharma-may2026-comparison/

0 · Reply

SuperGreenToday May. 8 at 3:24 AM

$AYTU

0 · Reply

Alain_Simard May. 7 at 6:36 PM

$AYTU they are reporting earnings on the 13??? Sounds prophetic to me!!! lol

0 · Reply

Alain_Simard May. 5 at 7:29 PM

$AYTU when is this 💩 reporting? Should be coming up soon…

0 · Reply

bullsnhorns2 Apr. 30 at 3:18 AM

$AYTU wooooow hadnt seen this stock in years just came to check it out... i made fkin BANK with then whole heal light sht!

0 · Reply

brucino Apr. 28 at 2:06 PM

$CXAI $GPRO $EYPT $DOMH $AYTU hot !!!💣🚀💥💰💰

0 · Reply

brucino Apr. 20 at 6:59 AM

$GPRO 💣🚀🛰️ ticker of the day $GPRO $DOMH $EYPT $AYTU $CXAI Let'go !!!!💣🚀

0 · Reply

Fibonacci5 Apr. 10 at 11:37 AM

$AYTU this is getting bot out.

1 · Reply

pamplon Apr. 2 at 10:45 PM

$AYTU This is really good news https://app.quotemedia.com/data/downloadFiling?webmasterId=102691&ref=319930169&type=PDF&symbol=AYTU&cdn=f2c683ce4fe38b388f07f88e95c50879&companyName=Aytu+BioPharma%2C+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-04-02

3 · Reply

inv1ncible Mar. 23 at 7:08 PM

$AYTU trash ceo and stock

0 · Reply

Market Cap	24.58M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	0.62

Volume	46,100
Avg Vol	45,062
Day's Range	N/A - N/A
Shares Out	10.73M
Stochastic %K	94%
Beta	0.28
Analysts	Strong Sell
Price Target	$9.33